{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinomas&page=41",
    "query": {
      "condition": "Head and Neck Squamous Cell Carcinomas",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 1529,
    "total_pages": 153,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinomas&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinomas&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T03:17:03.282Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00448552",
      "title": "Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-02",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2016-12-15",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448552"
    },
    {
      "nct_id": "NCT06054477",
      "title": "Study of ALE.C04 in Patients With Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ALE.C04",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alentis Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2023-10-30",
      "completion_date": "2025-02-12",
      "has_results": false,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 7,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • New Haven, Connecticut + 4 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06054477"
    },
    {
      "nct_id": "NCT00004865",
      "title": "Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-03-09",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 3,
      "location_summary": "Camden, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey",
      "locations": [
        {
          "city": "Camden",
          "state": "New Jersey"
        },
        {
          "city": "Lakewood",
          "state": "New Jersey"
        },
        {
          "city": "Long Branch",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004865"
    },
    {
      "nct_id": "NCT02646319",
      "title": "Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Cervical Squamous Cell Carcinoma",
        "Endometrial Carcinoma",
        "Malignant Uterine Neoplasm",
        "Recurrent Bladder Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Malignant Neoplasm",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Solid Neoplasm",
        "Stage III Bladder Cancer",
        "Stage III Prostate Cancer",
        "Stage III Renal Cell Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIA Cervical Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIB Cervical Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IVA Bladder Cancer",
        "Stage IVA Cervical Cancer",
        "Stage IVB Bladder Cancer",
        "Stage IVB Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nanoparticle Albumin-Bound Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2016-01",
      "completion_date": "2018-04-24",
      "has_results": false,
      "last_update_posted_date": "2019-06-06",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02646319"
    },
    {
      "nct_id": "NCT05768139",
      "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Solid Tumors, Adult"
      ],
      "interventions": [
        {
          "name": "STX-478",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Imlunestrant",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 880,
      "start_date": "2023-04-17",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 28,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05768139"
    },
    {
      "nct_id": "NCT03752398",
      "title": "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Excluding Uveal Melanoma)",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Cancer",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced Solid Tumors",
        "Undifferentiated Pleomorphic Sarcoma"
      ],
      "interventions": [
        {
          "name": "XmAb®23104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Yervoy® (ipilimumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 198,
      "start_date": "2019-05-01",
      "completion_date": "2024-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 18,
      "location_summary": "San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03752398"
    },
    {
      "nct_id": "NCT04106167",
      "title": "Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Advanced Solid Tumor",
        "Lymphoma",
        "Gastric Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma",
        "EGFR Positive Solid Tumor",
        "HER2-positive Breast Cancer",
        "Hepatocellular Carcinoma",
        "Small-cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Pancreas Cancer",
        "Melanoma",
        "NSCLC",
        "Urothelial Carcinoma",
        "Cervical Cancer",
        "Microsatellite Instability",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic natural killer (NK) cell",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2019-06-11",
      "completion_date": "2023-08-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04106167"
    },
    {
      "nct_id": "NCT06560645",
      "title": "A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Non-small Cell Lung Carcinoma",
        "SMARCA4 Mutation",
        "Esophageal Adenocarcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastric Squamous Cell Carcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Gastroesophageal Junction Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PRT7732",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prelude Therapeutics Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2024-11-04",
      "completion_date": "2026-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Detroit, Michigan • New York, New York + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06560645"
    },
    {
      "nct_id": "NCT00003118",
      "title": "Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "surgical procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "1997-10",
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2016-07-04",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 38,
      "location_summary": "La Jolla, California • San Francisco, California • Wilmington, Delaware + 29 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003118"
    },
    {
      "nct_id": "NCT00102635",
      "title": "4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Fenretinide (4-HPR)",
          "type": "DRUG"
        },
        {
          "name": "SCH66336",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2005-01-20",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2018-11-15",
      "last_synced_at": "2026-10-22T03:17:03.282Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00102635"
    }
  ]
}